Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $74.94

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned an average recommendation of “Hold” from the nineteen analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $74.94.

CRSP has been the subject of a number of recent research reports. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Truist Financial lowered their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $46.85 on Friday. The company has a market capitalization of $4.00 billion, a P/E ratio of -16.55 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10. The firm’s 50 day simple moving average is $47.80 and its 200 day simple moving average is $52.12.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the previous year, the business posted ($1.41) EPS. On average, equities analysts anticipate that CRISPR Therapeutics will post -5.2 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock valued at $1,917,679 in the last three months. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of CRSP. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares in the last quarter. SR One Capital Management LP bought a new position in CRISPR Therapeutics in the 1st quarter worth about $71,496,000. Farallon Capital Management LLC bought a new position in CRISPR Therapeutics in the 2nd quarter worth about $28,625,000. Avoro Capital Advisors LLC bought a new position in CRISPR Therapeutics in the 1st quarter worth about $28,599,000. Finally, Marshall Wace LLP bought a new position in CRISPR Therapeutics in the 2nd quarter worth about $10,078,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.